Fahmeedah Kamal is a Nephrology physician affiliated with Stanford Medicine. OpenAlex indexes 8 publications with 225 citations (h-index 2); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
300 Pasteur Dr
Stanford, CA 943052200
Telephone
650-723-4000Provider last certified this registry record 18 Apr 2024.
Clinical trials
- Belimumab With Rituximab for Primary Membranous Nephropathy
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
8 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Apellis Pharmaceuticals, Inc.Program year20251 payment
- Amgen Inc.Program year20251 payment
- Calliditas Therapeutics US Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
61.3%Angiotensin receptor blocker (ARB)24.1%Losartan Potassium63%Olmesartan Medoxomil37%Part D<11 patientsCalcium channel blocker11.7%Amlodipine Besylate100%Part D≥16 patients+ 3 more classes in this area
Blood & clotting
17.5%Erythropoiesis-stimulating Agent11.7%Procrit71%Retacrit30%Part D<11 patientsSolutions for parenteral nutrition5.8%Calcium Acetate100%Part D<11 patientsOther
9%Phosphate Binder5%Sevelamer Carbonate100%Part D<11 patientsDrugs for treatment of hyperkalemia and hyperphosphatemia4%Lokelma100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- How should we best manage the consequences of nephron loss in IgAN?
Nephrology Dialysis Transplantation
2025 - Kappa-Restricted IgA Nephropathy Treated Successfully With Targeted-Release Budesonide
Kidney International Reports
2025 - Considering the Treatment of IgA Nephropathy
Clinical Journal of the American Society of Nephrology
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Ranjana Advani, MD
Stanford Medicine
Michael Weisman, MD
Stanford Medicine
Maurice Ohayon, MD, DSC, PhD
Stanford Medicine
Bruno Medeiros, MD
Stanford Medicine
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”